<DOC>
	<DOCNO>NCT02469155</DOCNO>
	<brief_summary>The study evaluate antipsychotic efficacy ITI-007 randomize , double-blind , parallel-group , placebo- active-controlled , multi-center study patient diagnose schizophrenia acute exacerbation psychosis .</brief_summary>
	<brief_title>A Trial Assess Antipsychotic Efficacy ITI-007 Over 6 Weeks Treatment</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Risperidone</mesh_term>
	<mesh_term>Antipsychotic Agents</mesh_term>
	<criteria>male female subject race , age 1860 inclusive , clinical diagnosis schizophrenia experience acute exacerbation psychosis subject unable provide inform consent female subject pregnant breastfeeding subject judge medically inappropriate study participation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>